B Vitamins and Cognitive Decline — A Research Summary

B vitamins — particularly folate (B9), B6, and B12 — are essential cofactors in the methionine cycle, which regulates homocysteine metabolism. Elevated homocysteine is directly neurotoxic: it promotes excitotoxicity, impairs DNA repair, increases oxidative stress, and damages cerebrovascular endothelium. High homocysteine is associated with accelerated brain atrophy and increased Alzheimer's risk.

B vitamins lower homocysteine by supporting its conversion back to methionine (via folate and B12) or to cysteine (via B6). They also support myelin synthesis and contribute to neurotransmitter production (serotonin, dopamine, noradrenaline). B12 deficiency specifically causes subacute combined degeneration of the spinal cord and cognitive impairment that can mimic dementia.

The most important RCT is the VITACOG trial (Oxford, 2010): 168 older adults with mild cognitive impairment, given B6+B9+B12 vs. placebo for 2 years. In the treatment group, brain atrophy rate slowed by 53% on MRI — a dramatic finding. The effect was strongest in participants with elevated baseline homocysteine. A follow-up analysis found that the benefit was further amplified in participants with high omega-3 levels.

The COSMOS-Mind trial found no cognitive benefit from B vitamins in an unselected older adult population. The discrepancy with VITACOG likely reflects the importance of patient selection: B vitamins appear most effective in people with elevated homocysteine and/or MCI, not in unselected populations with normal homocysteine.

B12 deficiency specifically causes reversible cognitive impairment — correcting deficiency can restore function. B12 deficiency is common in older adults (affects 10-15% over 60) due to reduced gastric acid and intrinsic factor, and in people taking metformin for diabetes.

Promising, with important nuance. The evidence for B vitamins in people with elevated homocysteine or confirmed deficiency is genuinely strong — particularly the VITACOG brain atrophy finding. The evidence for B vitamins in people with normal homocysteine is weak. Testing homocysteine levels directs supplementation to those most likely to benefit.

VITACOG used: folic acid 800 mcg/day + B12 500 mcg/day + B6 20 mg/day. These are substantially higher than RDAs. For B12 specifically, sublingual or methylcobalamin forms are better absorbed than standard cyanocobalamin tablets, particularly in older adults with reduced gastric acid.

B vitamins are water-soluble and generally safe. High-dose folic acid (above 1mg/day) can mask B12 deficiency, so supplementing both together is preferable. Very high B6 doses (>100mg/day sustained) can cause peripheral neuropathy — not relevant at the doses used in cognitive health research. Methylcobalamin and methylfolate are preferred for people with MTHFR gene variants affecting folate metabolism.

Test homocysteine and B12. If homocysteine is elevated (above 12 micromol/L) or B12 is in the lower normal range, a B-complex supplement targeting these levels is one of the better-evidenced cognitive health interventions. For people with normal homocysteine and adequate B12, the evidence is weaker but the risk is minimal.